ALMDT Median Technologies

Median Technologies : Calendrier de communication financière du premier semestre 2025

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--

Regulatory News:

Median Technologies (FR0011049824, ALMDT, éligible PEA/PME), annonce la date de publication de ses résultats 2024 :

Publication

 

 

 

 

Date

Résultats 2024

 

 

 

 

29 avril 2025*

*Diffusion après clôture des marchés

A propos de Median Technologies : Pionnière dans les logiciels dispositifs médicaux et services d’imagerie innovants, Median Technologies exploite les technologies de pointe d’Intelligence Artificielle pour augmenter la précision des diagnostics précoces et des traitements de nombreux cancers. Les offres de Median, iCRO pour l’analyse et la gestion des images médicales dans les essais cliniques en oncologie ​​et eyonis™, suite de logiciels dispositifs médicaux basés sur les technologies de l’IA, permettent aux sociétés biopharmaceutiques et aux cliniciens de faire progresser les soins aux patients et d'accélérer le développement de nouvelles thérapies. La société française, également présente aux Etats-Unis et en Chine, est cotée sur le marché Euronext Growth (ISIN : FR0011049824, MNEMO : ALMDT). Median Technologies est éligible au PEA-PME. Plus d’informations sur

FR
14/01/2025

Underlying

ALMDTMedian Technologies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Median Technologies

Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: EIB loan signed, tied to equity raise and debt re...

Friday post-market, Median announced the final sign of the EIB loan agreement of EUR37.5m, which has been structured in three tranches (EUR19m, EUR8.5m, EUR10m) and with several key conditions being set to access the first one. These include i) a capital increase of at least EUR16m (including issua

ALMDT MEDIAN TECHNOLOGIES
07/14/25 July 14, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: CE mark filing keep eyonis on track, US launch be...

Yesterday post-market, Median announced that it has submitted the Class IIb CE marking filing for eyonis LCS, just a month after the FDA 510(k) submission, precisely sticking to the company's timeline guidance. Our confidence in a positive outcome remains high, as both submissions are underpinned b

ALMDT MEDIAN TECHNOLOGIES
07/02/25 July 2, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: eyonis LCS heads for FDA nod in Q3 2025

This morning, Median announced that it has submitted a 510(k) FDA filing for eyonis LCS, remaining on track with prior guidance and with a plausible clearance expected in Q3 2025. We are confident in a positive outcome, as the submission is underpinned by two pivotal studies—REALITY and RELIVE—whic

ALMDT MEDIAN TECHNOLOGIES
05/14/25 May 14, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: FY24 wrap-up signals cost discipline, outlook rei...

Median Technologies released its audited FY 2024 results, which contain no surprises versus the unaudited data already disclosed in prior updates (see Q4 2024 and Q1 2025 notes). Revenue for the year came in at EUR22.9m (+3.3% YoY), fully driven by iCRO services, and the order backlog stood at EUR7

ALMDT MEDIAN TECHNOLOGIES
04/30/25 April 30, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: eyonis on track, backlog at record high

Median Technologies started 2025 with a continued positive momentum on iCRO revenues, which grew 11% YoY to EUR6m, backed by a record EUR74.8m order backlog (+5.4% QoQ) driven by new wins from a Top 3 pharma client. Q1 was a pivotal quarter on the clinical side, with the pivotal RELIVE study for ey

ALMDT MEDIAN TECHNOLOGIES
04/25/25 April 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch